Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | STAT3 | P40763 | 2/20 | 0.44 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855220 | 1.00 | ALDH1A1 (0.44) | ALDH1A1STAT3PSMD10KMT2ACA12 | |
| SCHEMBL29923021 | 1.00 | ALDH1A1 (0.44) | ALDH1A1STAT3PSMD10KMT2ACA12 | |
| SCHEMBL21855288 | 1.00 | ALDH1A1 (0.44) | ALDH1A1STAT3PSMD10KMT2ACA12 | |
| SCHEMBL24624743 | 1.00 | ALDH1A1 (0.44) | ALDH1A1STAT3PSMD10KMT2ACA12 | |
| SCHEMBL3418749 | 1.00 | ALDH1A1 (0.44) | ALDH1A1STAT3PSMD10KMT2ACA12 | |
| SCHEMBL23754733 | 1.00 | ALDH1A1 (0.44) | ALDH1A1STAT3PSMD10KMT2ACA12 | |
| SCHEMBL29264617 | 0.92 | PSMD10 (0.43) | ALDH1A1STAT3PSMD10KMT2ACA12 | |
| SCHEMBL5556510 | 0.89 | ALDH1A1 (0.43) | ALDH1A1STAT3PSMD10KMT2ACA12 | |
| SCHEMBL25199152 | 0.89 | STAT3 (0.47) | ALDH1A1STAT3PSMD10KMT2ACA12 | |
| SCHEMBL17941005 | 0.87 | ALDH1A1 (0.43) | ALDH1A1STAT3KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4055019-B1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11866442-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230024442-A1 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11505617-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11479556-B1 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| EP-4055019-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-10-10 | — | — | US | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2393362-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | Immunogen, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2010091150-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | ALDH1A1 619/4885STAT3 1409/4885PSMD10 2517/4885 |
| US-11479556-B1 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | CBL, XIAP, BTK | ALDH1A1 4160/4885STAT3 1483/4885PSMD10 63/4885 |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | ALDH1A1 4160/4885STAT3 1483/4885PSMD10 63/4885 |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | ALDH1A1 4160/4885STAT3 1483/4885PSMD10 63/4885 |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | ALDH1A1 619/4885STAT3 1409/4885PSMD10 2517/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | ALDH1A1 4621/4885STAT3 1360/4885PSMD10 59/4885 |
| US-20230024442-A1 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, XIAP, CBL | ALDH1A1 3861/4885STAT3 1217/4885PSMD10 66/4885 |
| US-11866442-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | CBL, XIAP, BTK | ALDH1A1 4160/4885STAT3 1483/4885PSMD10 63/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | ALDH1A1 4714/4885STAT3 1298/4885PSMD10 73/4885 |
| US-11505617-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | ALDH1A1 625/4885STAT3 1391/4885PSMD10 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.